medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-3-18-23medsovet-130Research ArticleРИНОЛОГИЯRHINOLOGYКомплексная терапия хронического верхнечелюстного синуситаCombined treatment of acute maxillary sinusitisКрюковА. И.KryukovA. I.noemail@neicon.ruТуровскийА. Б.TurovskiyA. B.noemail@neicon.ruЦарапкинГ. Ю.TsarapkinG. Y.noemail@neicon.ruИзотоваГ. Н.IzotovaG. N.noemail@neicon.ruТовмасянА. С.TovmasyanA. S.noemail@neicon.ruФедоткинаК. М.FedotkinaK. M.noemail@neicon.ruГоринД. С.GorinD. S.noemail@neicon.ruМосковский научно-практический центр оториноларингологии им. Л.И. Свержевского Департамента здравоохранения г. МосквыРоссияMoscow Otorhinolaryngology Research and Practical Centre named after L.I. SverzhevskiyRussian Federation201530122015031823Copyright © Крюков А.И., Туровский А.Б., Царапкин Г.Ю., Изотова Г.Н., Товмасян А.С., Федоткина К.М., Горин Д.С., 20152015Крюков А.И., Туровский А.Б., Царапкин Г.Ю., Изотова Г.Н., Товмасян А.С., Федоткина К.М., Горин Д.С.Kryukov A.I., Turovskiy A.B., Tsarapkin G.Y., Izotova G.N., Tovmasyan A.S., Fedotkina K.M., Gorin D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/130

Хронический риносинусит является актуальной проблемой современной медицины. За последние 20 лет заболеваемость им увеличилась в 2 раза. По данным литературы, она повышается с возрастом: от 20 до 29 лет она составляет 2,7%, от 50 до 59 лет - 6,6% [1], что на фоне наблюдающегося старения населения придает проблеме воспалительных заболеваний околоносовых пазух (ОНП) еще большую значимость. Женщины страдают хроническим синуситом в 1,5 раза чаще, чем мужчины. Среди пациентов, находящихся на лечении в оториноларингологических стационарах, от 15 до 36% имеют заболевания околоносовых пазух носа (ОНп) [2].

Chronic rhinosinusitis is a relevant healthcare issue the incidence of which has increased twofold over the past 20 years. According to the literature, the incidence grows with age: in people aged 20 to 29 years, it equals 2.7%, and in people from 50 to 59 years - 6.6% [1]. Against a background of population ageing, inflammatory diseases of the paranasal sinuses (PNS) are becoming a challenge. Women suffer from chronic sinusitis 1.5 times more often than men. 15 to 36% of in-patients at ENT units are people suffering from diseases of the paranasal sinuses (PNS) [2].

хронический синуситреспираторные фторхинолоныинтраназальные кортикостероидыИНГКСchronic sinusitisrespiratory fluoroquinolonesintranasal corticosteroids (INCS)ReferencesBebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fLuoro-quinoLone against mycopLasmas. Antimicrob Agents Chemother, 1998, 42: 703-4.Bebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fLuoro-quinoLone against mycopLasmas. Antimicrob Agents Chemother, 1998, 42: 703-4.BLondeau J, Fass R. In vitro activity of BAY 12-8039, a new 8-methoxyquinoLone. Antimicrob Agents Chemother, 1997, 41: 1818-24.BLondeau J, Fass R. In vitro activity of BAY 12-8039, a new 8-methoxyquinoLone. Antimicrob Agents Chemother, 1997, 41: 1818-24.LosaetaL Е, Woodcock J, Andrews J, BosweLL F, BrenwaLd N, Wise R. In vitro activity of BAY 12-8039, a new fLuoroquinoLone. Antimicrob Agents Chemother, 1997, 41: 101-6.LosaetaL Е, Woodcock J, Andrews J, BosweLL F, BrenwaLd N, Wise R. In vitro activity of BAY 12-8039, a new fLuoroquinoLone. Antimicrob Agents Chemother, 1997, 41: 101-6.Duffy L, Kempf M, Crabb D, WaLL W, Herrington J. In vitro activity of moxifLoxacin and six other new antimicrobiaLs against MycopLasma pneu-moniae. Proceedings of the 39th ICAACf; 1999: 252, Sep 26-29; San Francisco.Duffy L, Kempf M, Crabb D, WaLL W, Herrington J. In vitro activity of moxifLoxacin and six other new antimicrobiaLs against MycopLasma pneu-moniae. Proceedings of the 39th ICAACf; 1999: 252, Sep 26-29; San Francisco.ULLmann U, Schubert S, Krausse R. Comparative in-vitro activity of LevofLoxacin, other fLuoroquinoLones, doxycycLine and erythromycin against UreapLasma ureaLyticum and MycopLasma hominis. J Antimicrob Chemother 1999, 43(C): 33-6.ULLmann U, Schubert S, Krausse R. Comparative in-vitro activity of LevofLoxacin, other fLuoroquinoLones, doxycycLine and erythromycin against UreapLasma ureaLyticum and MycopLasma hominis. J Antimicrob Chemother 1999, 43(C): 33-6.Gomez-Lus R, Adrian F, deL Campo R, et. aL. Comparative in vitro bacteriostatic and bactericidaL activity of trovafLoxacin, LevofLoxacin and moxifLoxacin against cLinicaL and environmentaL isoLates of LegioneLLa spp. Int J Antimicrob Agents, 2001, 18: 49-54.Gomez-Lus R, Adrian F, deL Campo R, et. aL. Comparative in vitro bacteriostatic and bactericidaL activity of trovafLoxacin, LevofLoxacin and moxifLoxacin against cLinicaL and environmentaL isoLates of LegioneLLa spp. Int J Antimicrob Agents, 2001, 18: 49-54.Cohen R. The antibiotic treatment of acute oti-tis media and sinusitis in chiLdren. Diagn MicrobioL Infect Dis, 1997, 27: 49-53.Cohen R. The antibiotic treatment of acute oti-tis media and sinusitis in chiLdren. Diagn MicrobioL Infect Dis, 1997, 27: 49-53.GwaLtney JM. Acute community-acquired sinusitis. CLin. Infect. Dis. 1996, 23: 12091223.GwaLtney JM. Acute community-acquired sinusitis. CLin. Infect. Dis. 1996, 23: 12091223.HampeL B. CLinicaL needs in the miLLennium -rhinosinusitis - the roLe of moxifLoxacin. - 1st Intern. MoxifLoxacin Symp., BerLin,1999, Ed. MandeLL L. Springer-VerLag, 2000: 174-177.HampeL B. CLinicaL needs in the miLLennium -rhinosinusitis - the roLe of moxifLoxacin. - 1st Intern. MoxifLoxacin Symp., BerLin,1999, Ed. MandeLL L. Springer-VerLag, 2000: 174-177.KLossek JM, Arvis P and study group. MoxifLoxacin versus trovafLoxacin in the treatment of acute bacteriaL maxiLLary sinusitis: a muLtinationaL, doubLe-bLind, randomised study. - 3rd Eur. Congr. Chemother., Madrid, 2000, Poster.KLossek JM, Arvis P and study group. MoxifLoxacin versus trovafLoxacin in the treatment of acute bacteriaL maxiLLary sinusitis: a muLtinationaL, doubLe-bLind, randomised study. - 3rd Eur. Congr. Chemother., Madrid, 2000, Poster.Stierna P. In: Kennedy DW, BoLger WE, Zinreich SJ, eds. Diseases of the sinuses: diagnosis and management. HamiLton, Ontario: B.C. Decker. 2001: 35-46.Stierna P. In: Kennedy DW, BoLger WE, Zinreich SJ, eds. Diseases of the sinuses: diagnosis and management. HamiLton, Ontario: B.C. Decker. 2001: 35-46.Brannan MD, SeiberLing V, CutLer DL et aL. Lack of systemic activity with intranasaL mometa-sone furoate. Ann ALLergy Asthma ImmunoL, 1997, 97: 198.Brannan MD, SeiberLing V, CutLer DL et aL. Lack of systemic activity with intranasaL mometa-sone furoate. Ann ALLergy Asthma ImmunoL, 1997, 97: 198.Lund VJ, Kennedy DW. Ann OtoL RhinoL LaringoL, 1995, 167(h): 17-21.Lund VJ, Kennedy DW. Ann OtoL RhinoL LaringoL, 1995, 167(h): 17-21.

The authors declare that there are no conflicts of interest present.